Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Feature|Articles|September 25, 2026
Oral L-Glutamine Could Be Pancreatic Cancer's Most Accessible Treatment Advance: Q&A with Dr. Jun Gong, MD
Author(s)Jun Gong, MD
Adding oral L-glutamine to standard chemo nearly tripled median OS in advanced pancreatic cancer — and what comes next.
Advertisement
Advertisement
Jun Gong, MD, associate professor of medicine and medical director of colorectal cancer at Cedars-Sinai, spoke with Pharmaceutical Executive about the results of a Phase I study that researched the impact of adding oral L-glutamine to first-line gemcitabine/nab-paclitaxel in treatment-naïve advanced pancreatic cancer.
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value.
CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Why effective RWD linkage starts with a specific research objective — and how tokenization, clean rooms, and AI make it possible.
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
Advertisement
Advertisement